

REMARKS

Claims 1-15 were filed in the originally filed PCT application under which the enclosed application is a national stage filing thereof.

Claims 3, 5, 6, 11 and 12 are amended.

Claims 16-20 are added.

No claims are canceled.

Accordingly, claims 1-20 will be pending upon entry of this amendment.

The claims are amended to remove multiple dependencies. New claims 16-20 are added to rewrite at least some of the multiple dependent claims into dependent form. No new matter is added.

CONCLUSION

Applicants believe that, in view of the amendments and remarks made above, this application is in condition for allowance. Early notice to that end is earnestly solicited.

The Commissioner is hereby authorized to charge any additional fees required, or to credit any overpayment to Deposit Account No. 16-1445.

In the event the examiner wishes to discuss any aspect of this response, please contact the attorney at the telephone number identified below.

Respectfully submitted,

Date May 10, 2006

/ Lyman H. Smith /
Lyman H. Smith
Attorney for Applicants
Registration No. 44,342

Pfizer Inc.
Patent Department

Attorney Docket No. PC25123A
Application No. Not assigned

MS 8260-1611
Eastern Point Road
Groton, CT 06340
(860)686-2372